Latest Headlines

Latest Headlines

Dog flu sweeps the U.S. with two more confirmed cases in Washington state

When a new strain of flu virus sickened 1,000 dogs and killed 5 in Chicago back in April, animal health experts wondered just how bad subsequent outbreaks would be. Now more cases are cropping up across the country, setting off red flags from vets and pet owners.

Merck lines up for a quick approval with its C. diff therapy

Merck is nearing FDA approval for its Clostridium difficile-fighting antibody, picking up the agency's priority review designation with the promise of a shortened vetting process.

Case Western, Merck team spotlights vaccine response predictors

Using a "systems vaccinology" approach, researchers at Case Western Reserve University School of Medicine and Merck Research Laboratories have published findings that suggest a new way to predict and enhance vaccine effectiveness, in particular with hepatitis B vaccination.

Merck to submit Ebola vaccine for regulatory approval in 2017

Merck's candidate is the furthest along in the quest for an Ebola vaccine, having posted interim Phase III data showing 100% efficacy last July. Now, the Big Pharma has won $5 million from Gavi, the global vaccine alliance, to help see its candidate through late-stage trials, licensure and prequalification by the WHO, and plans to submit the vaccine for regulatory approval by the end of 2017.

It's Merck vs. Merck as name confusion, complicated by social media, leads to legal showdown

Merck has won a legal battle over Merck, which in return says it will file a lawsuit against Merck. It sounds confusing, but confusion is the essence of the legal battle between Germany's Merck KGaA and U.S.-based Merck & Co., known as MSD outside the U.S. The companies are engaged in a dispute largely over the misunderstandings brought about from sharing the same name for nearly 125 years.

Merck reaches $830M settlement in long-running Vioxx litigation

Merck is closing a chapter in its seemingly never-ending saga for its painkiller Vioxx, agreeing to pay more than $800 million to settle a lawsuit over the med years after the company pulled its product from the market and shelled out billions to resolve additional suits.

#JPM16 Roundup: What you need to know on Pfizer, Sanofi and more

SAN FRANCISCO-- On Monday, we brought you the lowdown from the J.P. Morgan Healthcare Conference, with company presentations from pharma giants including Novartis and Merck & Co. Today, we're back with our latest roundup, big names and not-so-big.

WHO seeks to ease cholera vaccine shortage with EuBiologics approval

In a move aimed at doubling the world's cholera vaccine supply, the World Health Organization has given its nod to South Korean's EuBiologics to provide vaccines under its prequalification program.

BioLineRx joins Merck's clique of immuno-oncology partners

Israeli drug developer BioLineRx is partnering with Merck to see whether its in-development cancer therapy can work in tandem with an approved treatment that taps the power of the immune system, joining a long list of clinical partners.

GSK's Slaoui sees 'major' vaccine market disruption for Merck as shingles candidate progresses

SAN FRANCISCO-- Look out, Merck & Co.: GlaxoSmithKline expects its shingles candidate, Shingrix, to be a "major market disrupter" when it wins approval.